We have worked with Physiomics to help provide answers to some critical early clinical development questions with CCS1477, our novel p300/CBP inhibitor. The analysis performed by Physiomics and the interpretation and input from their modelling experts has been invaluable. We now have the comfort that the next steps we are taking with the development of CCS1477 are data driven and validated through expert modelling data. Thanks for all your help.
Physiomics has provided pk/pd modelling and data analysis expertise on several of our oncology projects. We have found the group to be talented, experienced and committed to delivering high quality results in a timely manner. Physiomics has helped us achieve a more quantitative and translational understanding of our novel molecules.
Construct Pharmacokinetic (PK) & Pharmacodynamic (PD) models to evaluate dose response.
Virtual Tumour will help you simulate tumours under the effects of any combination of anti-cancer agents.
Create mechanistic models to provide you with valuable insights.
Discover Physiomics’ innovative tool for the personalised treatment of cancer.
Virtual Tumour™ has been developed and refined based on years of experience in simulating a huge variety of cancer types, targets and drugs.
Prostate cancer affects 47,000 men per year in the UK and metastatic disease has less than a 30% 5-yr survival rate.
Physiomics is developing an innovative new Precision Dosing tool for the personalisation of docetaxel treatment of late stage castrate-resistant prostate cancer. If it were to be approved by regulatory authorities, the tool would potentially be able to:
Physiomics is increasingly working with companies at the stage of pre-clinical to clinical translation and has been able to work closely with its clients to provide supporting materials for use with third parties such as regulatory agencies. Here we provide an example from a project where the client was already in Phase 1 for one indication and wanted supporting evidence for dosing in a new indication.
*Combination case studies have shown that we can save between 8 and 18 groups of mice.
*Optimal combination schedules could be obtained in 3 months instead of 6 or 9 months.
*Predicted improved regimen which was better than expert opinion.
* [Achievements are derived from specific client projects and will vary subject to the project].